Vendor, South San Francisco, CA
Vaxart Biosciences Inc.
UEI WS6UMD1QTBC9, CAGE 4GQK7
1 award and $9,271,191 obligated between January 12, 2024 and February 2, 2026, 100% under full and open competition, against 1.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $9,271,191 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $9,271,191 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Oral Mucosal Vaccine for SARS-CoV2 Protection
Office of Assistant Secretary for Preparedness and Response, Aspr Administration for Strategic Preparedness and Response
Award noticeSan Francisco, CA75A50124C00002Awarded to Vaxart Biosciences Inc. for $9,271,193
Posted Jan 13, 2024
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00002Definitive Contract, January 12, 2024, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Clinical Trial Planning Activities for a Phase 2B Clinical Trial That Compares Vaxart'S XBB Vaccine Candidate to an Mrna Comparator to EvaluNAICS 541714, PSC AN42 | $9,271,191 |
- Places of performance
- California
- Product and service codes
- AN42 Health R&D Services; Health Care - Other; Applied Research
- Transactions
- 4 across 1 awards